

Phase 3 human clinical trial shows that metabolic activators accelerates recovery in COVID-19 patients

Stockholm, February 24—The Swedish biotechnology company ScandiBio Therapeutics today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19”. The study conducted in Turkey was published February 20 on [medRxiv](#), a preprint publication website. The study was conducted in partnership with California-based ChromaDex (NASDAQ:CDXC) that provided one of the four ingredients (nicotinamide riboside) through the ChromaDex External Research Program (CERP). The human phase 3 clinical study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving the activators. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. The results of the study build on findings from Phase 2 clinical data published in October 2020. The addition of the metabolic activators to standard of care not only reduced recovery time, but improved liver health and decreased levels of inflammatory markers as shown in the publication.

The randomized, placebo-controlled, and double-blind phase 3 clinical trial studied 309 outpatients at Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey. Patients were randomly assigned on a 3:1 basis to receive the metabolic activators or placebo in combination with the Turkish standard of care hydroxychloroquine (HCQ) or favipiravir (FP). Patients received the combined activators or placebo twice a day for 14 days and clinical status was evaluated through daily telephone visits.

“Our phase 3 data shows that metabolic activators significantly improve the recovery, liver health, and markers of inflammation of patients with COVID-19,” says lead investigator Dr. Adil Mardinoglu, KTH—Royal Institute of Technology in Sweden and King’s College London. “Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and we are pleased to find that the combination of these metabolic activators helps to remedy the stress put on the body of an infected patient.”

About ScandiBio Therapeutics:

ScandiBio Therapeutics is a biotechnology company founded by researchers from the KTH Royal Institute of Technology, Karolinska Institutet and Sahlgrenska Academy in Sweden. The science originates from research conducted at the Science for Life Laboratory in Stockholm (reference Dr Adil Mardinoglu and Professor Mathias Uhlén) together with researchers at the Sahlgrenska

Academy in Göteborg (reference Professor Jan Borén). A platform for AI-based modelling of biology and medicine has been developed to allow potential treatment of diseases with metabolic dysfunction. The company has developed drug candidates consisting of a combination of several metabolic activators aimed to improve for patients with mitochondrial dysfunction. A large number of human clinical trials have been initiated using one of these drug candidates to treat several diseases with metabolic problems, including COVID-19, Alzheimer's Disease, Parkinson's Disease and Non-Alcoholic Fat Liver Disease (NAFLD).

For more information, contact:

Dr Adil Mardinoglu, Chief Scientific Officer, email: adil.mardinoglu@scilifelab.se

Dr Jan Borén, Chief Medical Officer, email: Jan.Boren@wlab.gu.se

Dr Mathias Uhlén, Chairman of the Board, email: mathias.uhlen@scilifelab.se

For more information about ScandiBio Therapeutics, see: www.scandibio.com